Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 24, 2019 (7 years ago)

Divalproex Sodium Extended-Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviations: Product was exposed above 50% relative humidity levels during packaging operations.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS, USP Tablets, 250 mg, 100 count-unit dose carton, RX only, Manufactured by Dr. Reddy's Laboratories Ltd. Bachupally - 500 090 India. Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152. NDC # 0904-6363-61.

Affected NDC 0904-6363-61

Compare with the code on your package — it is the most precise check available.

Drug: Divalproex

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Divalproex Sodium
NDC 00904-6363
250 mg/1 Tablet, Film Coated, Extended Release
Oral
Major Pharmaceuticals Rx
Recalling firm
Major Pharmaceuticals
NDC code
0904-6363-61
Origin
MI, United States
Initiated by
N/A
FDA recall number
D-1583-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Divalproex recalls

See all

Other recalls by Major Pharmaceuticals

All 2019 recalls